Cited by 336

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Open access

Goetz, Matthew P., Sangkuhl, Katrin, Guchelaar, Henk‐Jan, Schwab, Matthias, Province, Michael, Whirl‐Carrillo, Michelle, Symmans, W. Fraser, McLeod, Howard L., Ratain, Mark J., Zembutsu, Hitoshi, Gaedigk, Andrea, van Schaik, Ron H., Ingle, James N., Caudle, Kelly E., Klein, Teri E.·2018·Clinical Pharmacology & Therapeutics

DOI 10.1002/cpt.1007

Open this paper in CoChat — free account

Abstract

Tamoxifen is biotransformed by CYP2D6 to 4‐hydroxytamoxifen and 4‐hydroxy N‐desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cpt.1007

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J., Bishop, Jr., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 998
Self-citation
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Self-citation
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
Self-citation
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404037 · Cited by 749
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., Haidar, C. E., Shen, D. D., Callaghan, J. T., Sadhasivam, S., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.254 · Cited by 680
Self-citation
Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
Self-citation
Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., Kharasch, E. D., & Skaar, T. C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.287 · Cited by 371
Self-citation
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Regan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
Madlensky, L., Natarajan, L., Tchu, S., Pu, M., Mortimer, J., Flatt, S. W., Nikoloff, D. M., Hillman, G., Fontecha, M. R., Lawrence, H. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.32 · Cited by 334
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
Lim, Y. C., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0926-7 · Cited by 309
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
Mürdter, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W., Fasching, P. A., Fehm, T., Eichelbaum, M., Schwab, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.27 · Cited by 270
Self-citation
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Rae, J. M., Drury, S., Hayes, D. F., Stearns, V., Thibert, J. N., Haynes, B. P., Salter, J., Sestak, I., Cuzick, J., & Dowsett, M. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs126 · Cited by 259
Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998
Li, C. I., Daling, J. R., & Malone, K. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.088 · Cited by 245
Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues.
Borgna, J., & Rochefort, H. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70058-1 · Cited by 234
The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells
Wu, X., Hawse, J. R., Subramaniam, M., Goetz, M. P., Ingle, J. N., & Spelsberg, T. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3933 · Cited by 225
Self-citation
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
Saladores, P., Mürdter, T., Eccles, D., Chowbay, B., Zgheib, N. K., Winter, S., Ganchev, B., Eccles, B., Gerty, S., Tfayli, A., et al. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.34 · Cited by 199
Self-citation
Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
Irvin, W. J., Walko, C. M., Weck, K. E., Ibrahim, J. G., Chiu, W. K., Dees, E. C., Moore, S. G., Olajide, O. A., Graham, M. L., Canale, S. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4427 · Cited by 181
Self-citation
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer
JORDAN, V (2007) · Steroids · doi:10.1016/j.steroids.2007.07.009 · Cited by 177
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
Province, M. A., Goetz, M. P., Brauch, H., Flockhart, D. A., Hebert, J. M., Whaley, R., Suman, V. J., Schroth, W., Winter, S., Zembutsu, H., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.186 · Cited by 175
Self-citation
CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
Goetz, M. P., Suman, V. J., Hoskin, T. L., Gnant, M., Filipits, M., Safgren, S. L., Kuffel, M. J., Jakesz, R., Rudas, M., Greil, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2153 · Cited by 129
Self-citation
PharmGKB summary
Klein, D. J., Thorn, C. F., Desta, Z., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283656bc1 · Cited by 117
Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)
Tseng, E., Walsky, R. L., Luzietti, R. A., Harris, J. J., Kosa, R. E., Goosen, T. C., Zientek, M. A., & Obach, R. S. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057000 · Cited by 95
The Top 100 Drug Interactions: A Guide to Patient Management
Carpenter, J. F. (2002) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr2002324294 · Cited by 69
Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer
Lønning, P. E., Lien, E. A., Lundgren, S., & Kvinnsland, S. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199222050-00002 · Cited by 68
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
Schroth, W., Winter, S., Mürdter, T. E., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00582 · Cited by 67
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle, J. N., Suman, V. J., JOHNSON, P. A., Krook, J. E., Mailliard, J. A., Wheeler, R. H., Loprinzi, C. L., Perez, E. A., Jordan, V. C., & Dowsett, M. (1999) · PubMed · Cited by 58
Self-citation
Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
Sanchez‐Spitman, A., Moes, D. J. A. R., Gelderblom, H. A. J., Dezentjé, V. O., Swen, J. J., & Guchelaar, H. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2323-2 · Cited by 54
Self-citation
CYP2C19*2Polymorphism is Associated with Increased Survival in Breast Cancer Patients Using Tamoxifen
Ruiter, R., Bijl, M. J., van Schaik, R. H., Berns, E. M. J. J., Albert Hofman, D., Coebergh, J. W. W., van Noord, C., Visser, L. E., & Stricker, B. H. C. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.112 · Cited by 50
The CYP2C19*2 Genotype Predicts Tamoxifen Treatment Outcome in Advanced Breast Cancer Patients
van Schaik, R. H., Kok, M., Sweep, F. C. G. J., van Vliet, M., van Fessem, M., Gelder, M. E. M., Seynaeve, C., Lindemans, J. W., Wesseling, J., Veer, L. V. ‘., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.54 · Cited by 49
Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study
Zembutsu, H., Nakamura, S., Akashi‐Tanaka, S., Kuwayama, T., Watanabe, C., Takamaru, T., Takei, H., Ishikawa, T., Miyahara, K., Matsumoto, H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1779 · Cited by 39
Self-citation
Association ofCYP2C19*2and associated haplotypes with lower norendoxifen concentrations in tamoxifen‐treated Asian breast cancer patients
Lim, J. S. L., Sutiman, N., Muerdter, T. E., Singh, O., Cheung, Y. B., Ng, R. C. H., Yap, Y. S., Wong, N. S., Ang, P., Dent, R. A., et al. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12886 · Cited by 25
Self-citation

The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Biological sex differences in pharmacokinetics and adverse drug reactions
Aljohmani, A., & Yildiz, D. (2026) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-025-04721-8 · Cited by 35
Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects
Keller, D. N., Medwid, S. J., Ross, C. D., Wigle, T. J., & Kim, R. B. (2023) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000486 · Cited by 7

See all 336

Authors: Goetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl‐Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., Gaedigk, A., van Schaik, R. H., Ingle, J. N., Caudle, K. E., & Klein, T. E.
Venue: Clinical Pharmacology & Therapeutics
Publisher: Wiley
Published: 2018-01-31
Volume: 103
Issue: 5
Pages: 770-777
ISSN: 0009-9236 (ISSN-L)
1532-6535
DOI: 10.1002/cpt.1007
OpenAlex: W2792046032
Cited by: 336
References: 43
FWCI: 40.73
Type: journal article
Language: en
Open access: green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources